Actavis UK Limited v. Eli Lilly
United Kingdom Supreme Court
[2017] UKSC 48 (2017)
- Written by Elliot Stern, JD
Facts
Eli Lilly & Company (plaintiff) had a European patent for a cancer treatment that worked by combining a compound called pemetrexed disodium with vitamin B12. This combination allowed for the use of pemetrexed, known to be effective against cancerous tumors, without the potentially serious side effects of taking pemetrexed alone. Eli Lilly sued Actavis UK Unlimited (Actavis) (defendant) for infringement of its patent. The Actavis products alleged to violate the Eli Lilly patent were all pemetrexed compounds that were used together with Vitamin B12 to treat cancer. However, the compounds used by the Actavis products were pemetrexed diacid, pemetrexed ditromethamine, and pemetrexed dipotassium, not pemetrexed disodium. Eli Lilly’s patent claims specified the use of pemetrexed disodium for inhibiting tumor growth in combination with Vitamin B12. Actavis claimed that, as their products did not use pemetrexed disodium, they would not infringe Eli Lilly’s patent claims.
Rule of Law
Issue
Holding and Reasoning (Neuberger, C.J.)
What to do next…
Here's why 811,000 law students have relied on our case briefs:
- Written by law professors and practitioners, not other law students. 46,300 briefs, keyed to 988 casebooks. Top-notch customer support.
- The right amount of information, includes the facts, issues, rule of law, holding and reasoning, and any concurrences and dissents.
- Access in your classes, works on your mobile and tablet. Massive library of related video lessons and high quality multiple-choice questions.
- Easy to use, uniform format for every case brief. Written in plain English, not in legalese. Our briefs summarize and simplify; they don’t just repeat the court’s language.